10-Q: Turn Therapeutics Lists on Nasdaq, Raises Capital Amid Losses

Turn Therapeutics Inc. completed its Nasdaq direct listing and secured significant financing, but reported increased net losses and faces going concern doubts.

Summary

• Turn Therapeutics Inc. completed its direct listing on The Nasdaq Global Market under the ticker TTRX on October 8, 2025.
• The company reported a net loss of $3.47 million for the nine months ended September 30, 2025, significantly higher than the $1.45 million loss for the same period in 2024.
• General and administrative expenses increased by $2.2 million to $3.4 million for the nine months ended September 30, 2025, primarily due to legal and advisory fees related to the direct listing.
• Cash and cash equivalents increased to $3.11 million as of September 30, 2025, from $0.87 million at December 31, 2024, largely due to financing activities.
• The company raised approximately $1.93 million from a Regulation Crowdfunding offering, $227 thousand from a Regulation A+ offering, and $2.74 million from a Regulation D offering during the nine months ended September 30, 2025.
• A 2-for-1 forward stock split was approved and became effective on September 30, 2025.
• The company initiated a Phase 2-equivalent clinical trial for GX-03 for moderate-to-severe eczema in July 2025, with enrollment progressing as expected and completion anticipated in the first half of 2026.
• Management estimates current cash will fund operations into the first quarter of 2026, raising substantial doubt about the company's ability to continue as a going concern.
• An additional $18.0 to $20.0 million is anticipated to be required for planned Phase 3 trials for eczema and onychomycosis, and $1.5 million to $2.5 million for the vaccine program.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company achieved a significant milestone with its Nasdaq listing and secured substantial capital commitments, the increased net losses, negative cash flow, and explicit 'going concern' warning highlight significant financial challenges and high operational burn rate. The future success is heavily reliant on successful clinical trials and further capital raises, which carry inherent risks.

Positives

• Successfully completed a direct listing on The Nasdaq Global Market (TTRX) on October 8, 2025, enhancing market visibility and access to capital.
• Significantly increased cash and cash equivalents to $3.11 million as of September 30, 2025, from $0.87 million at December 31, 2024, providing immediate liquidity.
• Secured substantial financing through various offerings, including $1.93 million from Regulation Crowdfunding, $227 thousand from Regulation A+, and $2.74 million from Regulation D.
• Entered into a GEM Share Purchase Agreement for up to $85.0 million in common stock purchases, providing a potential source of future capital.
• Initiated a Phase 2-equivalent clinical trial for GX-03 for moderate-to-severe eczema in July 2025, with enrollment progressing as expected.
• Remediated a previously identified material weakness in internal control over financial reporting as of September 30, 2025, improving financial reporting reliability.
• Preclinical in-vivo xenograft studies for herpes zoster ophthalmicus and basal cell carcinoma showed promising results, suggesting broader platform potential.

Negatives

• Net loss significantly increased to $3.47 million for the nine months ended September 30, 2025, compared to $1.45 million for the same period in 2024.
• Experienced negative cash flows from operations of $1.39 million for the nine months ended September 30, 2025.
• Accumulated deficit grew to $22.67 million as of September 30, 2025.
• Management has raised substantial doubt about the company's ability to continue as a going concern, as current cash is only sufficient into the first quarter of 2026.
• Significant additional funding of $18.0 to $20.0 million is required for planned Phase 3 trials and $1.5 million to $2.5 million for the vaccine program, which is not yet secured.
• General and administrative expenses increased substantially by $2.2 million for the nine months ended September 30, 2025, largely due to direct listing costs.

Risks

• Future financing agreements may lead to increased dilution for existing shareholders and sales of common stock in the open market, which could adversely impact the trading price.
• The capital markets are unpredictable, and the company may not be able to secure additional financing on acceptable terms, or at all, which could materially adversely affect the business.
• Failure to maintain effective internal controls over financial reporting could result in material misstatements, legal and regulatory liabilities, delisting from Nasdaq, and a decline in stock price.
• The business is dependent on the successful development, regulatory approval, and commercialization of its products and product candidates; failure in any of these areas could have a material adverse effect.
• Changes in tax laws, such as the Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA), or their implementation/interpretation, could adversely affect the company's business and financial condition.
• An active trading market for the common stock may not develop or be sustained after the listing, leading to illiquidity and volatile market prices.
• The number of shares sold to GEM under the Share Purchase Agreement, the prices, and actual proceeds are unpredictable, and any substantial sales could cause significant dilution to stockholders.

Future Outlook

The company expects to continue incurring substantial operating losses as it invests in research and development for later-stage clinical trials. Cash and cash equivalents are estimated to fund operations into the first quarter of 2026. Significant additional funding of $18.0 to $20.0 million is required for planned Phase 3 trials for eczema and onychomycosis, and $1.5 million to $2.5 million for the vaccine program. The company intends to finance operations through potential public or private equity offerings, debt financings, and collaborations, including utilizing the GEM Share Purchase Agreement. Research and development expenses are expected to increase substantially as clinical programs advance.

Management Comments

• We will continue to incur costs and expenses related to our ongoing operations until we successfully commercialize, develop, obtain regulatory approval for and gain market acceptance of products and product candidates and achieve revenues adequate to support our operations.
• Based on our current operating plan, we estimate that our cash and cash equivalents as of September 30, 2025, will be sufficient to fund our operating expenses and research and development expenditure requirements into the first quarter of 2026.
• We expect to finance our operations through potential public or private equity offerings, debt financings or other capital sources, including current or potential future collaborations, licenses and other similar arrangements.
• We expect our general and administrative expenses to increase as a result of operating as a public company, including costs to comply with rules and regulations, compliance and reporting obligations, and increased expenses for insurance, investor relations and professional services.
• We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to clinical programs associated with our product candidates, including but not limited to clinical trials.

Industry Context

Turn Therapeutics operates in the highly competitive and capital-intensive pharmaceutical and medical device development industry. Its focus on dermatological diseases (eczema, onychomycosis) and innovative platform technology (PermaFusion) positions it in a market with significant unmet needs. The development of a thermostable intranasal vaccine, in partnership with a global nonprofit, aligns with broader industry trends towards addressing global health challenges and improving vaccine accessibility, particularly in low-resource settings. The company's strategy of out-licensing FDA-cleared medical devices while focusing on drug development is a common approach for biotech firms to generate non-dilutive capital and validate technology platforms.

Comparison to Industry Standards

• The company's accumulated deficit of $22.67 million and ongoing net losses are typical for a development-stage pharmaceutical company that has not yet commercialized its primary drug candidates.
• The reliance on equity and debt financing, including crowdfunding and private offerings, is standard for early-stage biotech companies before significant product revenue generation.
• The substantial doubt about going concern is a critical disclosure, common in the biotech sector where R&D costs are high and regulatory approvals are uncertain, but it signals a higher financial risk compared to established, profitable pharmaceutical companies.
• The 2-for-1 forward stock split is a corporate action that can increase share liquidity and potentially make the stock more attractive to a broader range of investors, a strategy sometimes employed by companies seeking to enhance market presence post-listing.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be party to litigation, arbitration, claims, or other legal proceedings in the ordinary course of business. As of September 30, 2025, no litigation or legal proceedings are considered probable to have a material adverse effect on the business.

Related Party Transactions

• Engaged Davis Polk & Wardwell LLP for legal advisory services for the public listing of Common Stock on a registered stock exchange.
• Arthur Golden, a senior counsel at Davis Polk & Wardwell LLP, joined the company's board of directors on September 30, 2025.
• Accrued unbilled legal costs of approximately $1.2 million payable to Davis Polk & Wardwell LLP for the nine months ended September 30, 2025, recorded as general and administrative expenses.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from future equity issuances under the GEM Purchase Agreement and other financings. The direct listing provides liquidity but market price volatility is a risk. The 2-for-1 stock split retroactively adjusted share counts.
• **Employees**: Stock-based compensation is a component of general and administrative expenses, and new equity incentive plans (2025 Omnibus Incentive Plan) are in place to attract and retain talent. Management changes include new director and certifying officers.
• **Customers/Patients**: Progress in clinical trials for eczema and onychomycosis, and development of a thermostable vaccine, could lead to new therapeutic options. Out-licensing of medical devices aims to expand product reach.
• **Creditors**: The 'going concern' warning indicates increased risk, as the company's ability to meet future obligations depends on securing additional financing.
• **Suppliers/Vendors**: Concentration of accounts payable with two vendors (16% of total as of Sep 30, 2025) indicates reliance, but overall accounts payable increased significantly, suggesting higher operational activity.

Next Steps

• Complete the Phase 2-equivalent clinical trial for GX-03 for moderate-to-severe eczema in the first half of 2026.
• Engage a Contract Research Organization (CRO) partner in 2026 to design and initiate Phase 3-equivalent pivotal trials for GX-03 for onychomycosis.
• Initiate in-vivo studies for the intranasal thermostable vaccine project in partnership with a global non-profit in the near future.
• Seek additional financing through public or private equity offerings, debt financings, or strategic collaborations to fund operations and planned R&D activities.
• Continue to monitor and enhance internal controls over financial reporting.

Key Dates

Recommendation

Turn Therapeutics has achieved a significant milestone with its Nasdaq direct listing and has secured substantial capital commitments, which are positive for its long-term development. However, the company faces considerable financial challenges, including a rapidly increasing net loss, negative cash flow from operations, and an explicit 'going concern' warning, indicating that current cash is insufficient to fund operations beyond Q1 2026 without further capital. While the pipeline shows promise, particularly with the eczema trial progressing and preclinical data for other indications, the high burn rate and reliance on future dilutive financing present significant risks. A 'hold' recommendation is appropriate for investors who are already exposed and believe in the long-term potential of the PermaFusion platform, but new investors should exercise extreme caution due to the high financial risk and uncertainty surrounding future funding and regulatory approvals.

Keywords

Pharmaceutical development, Medical device, Dermatology, Eczema, Onychomycosis, Thermostable vaccine, PermaFusion, Nasdaq listing, Capital raise, Clinical trials, Going concern, Biotech, SEC filing